SecBot SecBot
PRESS-RELEASE ·Filed Apr 19, 2026

XENE

Xenon Pharmaceuticals Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The data support azetukalner as a best-in-class therapy for treatment-resistant epilepsy, with strong efficacy, long-term seizure freedom, and patient-friendly dosing. With NDA submission expected in Q3 2026, XENE is a compelling near-term regulatory catalyst play. Traders should monitor for FDA feedback and potential partnership interest.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$57.09
T+0 close · Apr 19, 2026 · via day close
Latest settled
+18.60%
T+60 · $67.71
Vs SPY
+11.82%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $57.09entry
  2. T+1 · 7mo ago −1.21%α −0.56% · $56.40
  3. T+5 · 7mo ago −4.96%α −5.87% · $54.26
  4. T+20 · 6mo ago −5.92%α −10.12% · $53.71
  5. T+60 · 4mo ago +18.60%α +11.82% · $67.71
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xenon Pharmaceuticals presented positive Phase 3 X-TOLE2 and long-term open-label data for azetukalner in focal onset seizures at the AAN 2026 meeting, showing statistically significant and durable seizure reduction, with nearly 40% of long-term patients achieving at least 12 months of seizure freedom. The company plans to submit an NDA to the FDA in Q3 2026.

Key Facts

  • Azetukalner 25 mg achieved a 53.2% reduction in monthly seizure frequency vs. 10.4% for placebo (p<0.0001) in the Phase 3 X-TOLE2 trial.
  • Long-term data from the X-TOLE OLE study show 38.2% of patients treated for ≥48 months achieved at least 12 months of seizure freedom.
  • Azetukalner demonstrated consistent safety with low rates of serious adverse events (5.6% in 25 mg group vs. 2.4% placebo).
  • Xenon plans to submit an NDA for azetukalner in epilepsy to the FDA in Q3 2026.

Financial Impact

High commercial potential in a $5B market; azetukalner could capture significant share given best-in-class efficacy and no-titration advantage.

revenuemarketCapeps

Risk Factors

  • Regulatory delay or rejection of NDA submission
  • Competition from established ASMs and emerging therapies
  • Potential safety signals in larger patient populations

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276673

Track record

19 reports on XENE

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +7.28% at T+60 after the Mar 13, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 8h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 19, 2026